Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2016 | 9/30/2016 | 6/30/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | – | $0 |
| % Growth | 61.3% | – | – | – |
| Gross Profit | $0 | $0 | – | $0 |
| % Margin | 64% | 40.9% | – | 38% |
| EBITDA | -$0 | -$0 | – | -$0 |
| % Margin | -12.7% | -121.7% | – | -196.6% |
| Net Income | -$0 | -$0 | – | -$0 |
| % Margin | -42.4% | -134.2% | – | -205.3% |
| EPS Diluted | 0 | 0 | – | 0 |
| % Growth | – | – | – | – |
| Operating Cash Flow | – | – | – | – |
| Capital Expenditures | – | – | – | – |
| Free Cash Flow | – | – | – | – |